Mylan’s Eszopiclone Tablets have been released in 1 mg, 2mg and 3mg pills which are used to treat insomnia. The company’s generic version of Lunesta has received final approval from the U.S. Food and Drug Administration (FDA).
Meanwhile, Teva has announced the launch of a generic version of the sleeping pills. Lunesta tablets account for approximately $852 million in sales in the U.S.
Lunesta isn’t the only sleeping pill making headlines lately as the FDA recently ordered lower doses for rival insomnia remedy Ambien.
TEVA stock is down about 1.3% and MYL stock is down over 0.8% Tuesday.
More Health News